Nosocomial infections: new therapeutic alternatives

Abstract

This symposium on nosocomial infections, antimicrobial resistance and the benefits of doripenem in this setting was held in Madrid, Spain, on 7 October 2009, and was supported by Janssen-Cilag. The topic was presented under an interdisciplinary approach by different international experts in the field.

Financial & competing interests disclosure

This article was sponsored by Janssen-Cilag Spain. José Antonio Buron is an employee of Janssen-Cilag Spain. Gian Maria Rossolini, Santiago Grau Cerrato, Jordi Rello, Rafael Zaragoza and José Angel García Rodriguez have received personal compensation for activities (consulting, clinical research and presenting at conferences) with Janssen-Cilag Spain. Javier Garau is in receipt of research funding from AstraZeneca and has received honoraria or has been an advisor for Novartis, GlaxoSmithKline, Pfizer, Bayer, Astellas and Janssen-Cilag. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript and was provided by ContentEdNet and funded by Janssen-Cilag Spain.